# US 2023/0183067 A1 · Sodium thiosulfate-containing pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0183067 A1
- Document ID: US20230183067A1
- Status: Published application
- Kind: A1
- Application number: 18/108,803
- Filed: 2023-02-13
- Published: 2023-06-15
- Earliest claimed: 2009-07-08
- Assignees: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals
- Applicants: Hope Medical Enterprises, Inc. dba Hope Pharmaceuticals
- Inventors: Craig Sherman; Catherine Marie Smith; Kevin Robert Wirtz; Erich Schulze
- Web page: https://patentgrep.com/patent/US20230183067A1

## CPC

- C01B 17/64: Thiosulfates; Dithionites; Polythionates
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 31/60: Salicylic acid; Derivatives thereof
- A61K 31/727: Heparin; Heparan
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 33/22: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/14: for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 17/12: Keratolytics, e.g. wart or anti-corn preparations
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C01P 2006/80: Compositional purity
- Y10T 436/23: Carbon containing
- C01B: NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; {METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C01P: INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

Pharmaceutical grade sodium thiosulfate which contains no greater than about 10 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% by weight of sulfite, contains no greater than about 0.5% by weight of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities, wherein a 10% aqueous solution of the sodium thiosulfate at 25° C. is colorless and has a pH between about 6.0 and about 8.0.

### Claim 22 (depends on 21)

The pharmaceutical grade sodium thiosulfate of claim 21, wherein the pharmaceutical grade sodium thiosulfate contains no greater than about 8 ppm of non-purgeable organic carbon.

### Claim 23 (depends on 21)

The pharmaceutical grade sodium thiosulfate of claim 21, wherein the pharmaceutical grade sodium thiosulfate is anhydrous.

### Claim 24

A pharmaceutical composition comprising pharmaceutical grade sodium thiosulfate in an aqueous pharmaceutically acceptable carrier, wherein the sodium thiosulfate used to prepare the pharmaceutical composition contains no greater than about 10 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% by weight of sulfite, contains no greater than about 0.5% by weight of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein the aqueous pharmaceutically acceptable carrier is sterile water for injection.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the pharmaceutical grade sodium thiosulfate contains no greater than about 8 ppm of non-purgeable organic carbon.

### Claim 27 (depends on 25)

The pharmaceutical composition of claim 25, wherein the composition is formulated for oral, parenteral, inhalation, nasal, intravesical, vaginal, rectal, sublingual, ophthalmic, or topical administration.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, wherein the composition is formulated for parenteral administration.

### Claim 29 (depends on 28)

The pharmaceutical composition of claim 28, wherein the composition is formulated as a single dosage form.

### Claim 30 (depends on 25)

The pharmaceutical composition of claim 25, further comprising an isotonic agent and one or more pH adjusting agents.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, which is sterile and suitable for intravenous administration, wherein the isotonic agent is potassium chloride, present at about 4.40 mg/mL and the pH adjusting agents are boric acid, present at about 2.80 mg/mL, and sodium hydroxide.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, wherein the pharmaceutical grade sodium thiosulfate is present at a concentration of about 250.0 mg/mL of sodium thiosulfate pentahydrate as measured on an anhydrous basis.

### Claim 33 (depends on 25)

The pharmaceutical composition of claim 25, wherein the pharmaceutical grade sodium thiosulfate used to make the composition is anhydrous.

### Claim 34 (depends on 31)

The pharmaceutical composition of claim 31, comprising about 140 mg boric acid and about 220 mg potassium chloride.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, further comprising pharmaceutical grade sodium thiosulfate present at a concentration of about 12.5 grams of sodium thiosulfate pentahydrate as measured on an anhydrous basis.

### Claim 36

A pharmaceutical composition comprising pharmaceutical grade sodium thiosulfate in water, wherein the sodium thiosulfate used to prepare the pharmaceutical composition contains no greater than about 10 ppm of non-purgeable organic carbon, contains no greater than about 0.05 ppm of mercury, contains no greater than about 2 ppm of aluminum, contains no greater than about 0.003% by weight of selenium, contains no less than about 98% by weight and no greater than about 102% by weight of sodium thiosulfate on an anhydrous basis measured by ion chromatography, has a heavy metal content of no greater than about 10 ppm, contains no greater than about 200 ppm of chloride, contains no greater than about 0.001% by weight of sulfide, contains no greater than about 0.002% by weight of iron, contains no greater than about 0.01% by weight of calcium, contains no greater than about 0.005% by weight of potassium, contains no greater than about 0.1% by weight of sulfite, contains no greater than about 0.5% by weight of sulfate, contains no greater than about 3 ppm of arsenic, contains no greater than about 0.001% by weight of lead, has total aerobic count of microbial load of no greater than about 100 CFU/g, has total yeast and mold count of no greater than about 20 CFU/g, contains no greater than about 0.02 EU/mg of bacterial endotoxins, contains no greater than about 0.002% by weight of nitrogen compounds, contains no greater than about 0.005% by weight of insoluble matter, contains no greater than 0.01% by weight of residual anti-caking agent, and contains no greater than ICH Q3C (R3) limits of organic volatile impurities, wherein the pharmaceutical composition is a sterile solution intended for intravenous injection prepared by combining said pharmaceutical grade sodium thiosulfate, boric acid, potassium chloride, sodium hydroxide and water.

### Claim 37 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical grade sodium thiosulfate used to prepare the composition is anhydrous sodium thiosulfate.

### Claim 38 (depends on 36)

The pharmaceutical composition of claim 36, wherein the pharmaceutical grade sodium thiosulfate used to prepare the composition is sodium thiosulfate pentahydrate.

### Claim 39 (depends on 25)

A method for treating or preventing platinum-induced ototoxicity, platinum-induced nephrotoxicity, cyanide poisoning, calciphylaxis, vascular calcification associated with atherosclerosis or a fungal infection of the skin, nailbeds, or nails, comprising administering to a subject having or at risk of having platinum-induced ototoxicity, platinum-induced nephrotoxicity, cyanide poisoning, calciphylaxis, vascular calcification associated with atherosclerosis or a fungal infection of the skin, nailbeds, or nails a therapeutically effective amount of the pharmaceutical composition of claim 25.

### Claim 40 (depends on 29)

The method of claim 29, wherein said subject is treated for cyanide poisoning.

### Claim 41 (depends on 40)

The method of claim 40, wherein the pharmaceutical grade sodium thiosulfate used to make the composition is anhydrous.

### Claim 42 (depends on 29)

The method of claim 29, wherein platinum-induced ototoxicity is prevented in said patient.

### Claim 43 (depends on 42)

The method of claim 42, wherein the pharmaceutical grade sodium thiosulfate used to make the composition is anhydrous.

### Claim 44 (depends on 21)

A method for preparing pharmaceutical grade sodium thiosulfate of claim 21, which comprises the steps of: a) contacting sodium sulfite with sulfur in a solvent to yield a reaction mixture; b) filtering the reaction mixture to yield a solution; c) concentrating the solution; d) exposing the solution to activated carbon; e) filtering the solution with activated carbon; and f) crystallizing the sodium thiosulfate from the solution.
